# Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

> **NCT01587222** · PHASE2 · WITHDRAWN · sponsor: **Anna Cruceta**

## Conditions studied

- Fibrosis
- Renal Failure
- Hepatorenal Syndrome

## Interventions

- **DRUG:** Albumin
- **DRUG:** Midodrine
- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT01587222
- **Lead sponsor:** Anna Cruceta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07
- **Primary completion:** 2017-07
- **Final completion:** 2017-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** the sponsor did not provide the treatment
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01587222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01587222, "Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01587222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*